Use of a Targeted Urine Proteome Assay (TUPA) to identify protein biomarkers of delayed recovery after kidney transplant

Kenneth R. Williams, Christopher M. Colangelo, Lin Hou, Lisa Chung, Justin M. Belcher, Thomas Abbott, Isaac E. Hall, Hongyu Zhao, Lloyd G. Cantley, Chirag Parikh

Research output: Contribution to journalArticle

Abstract

Purpose: Development of delayed graft function (DGF) following kidney transplant is associated with poor outcomes. An ability to rapidly identify patients with DGF versus those with immediate graft function (IGF) may facilitate the treatment of DGF and the research needed to improve prognosis. The purpose of this study was to use a Targeted Urine Proteome Assay to identify protein biomarkers of delayed recovery from kidney transplant. Experimental design: Potential biomarkers were identified using the Targeted Urine Proteome (MRM) Assay to interrogate the relative DGF/IGF levels of expression of 167 proteins in urine taken 12–18 h after kidney implantation from 21 DGF, 15 SGF (slow graft function), and 16 IGF patients. An iterative Random Forest analysis approach evaluated the relative importance of each biomarker, which was then used to identify an optimum biomarker panel that provided the maximum sensitivity and specificity with the least number of biomarkers. Conclusions and clinical relevance: Four proteins were identified that together distinguished DGF with a sensitivity of 77.4%, specificity of 82.6%, and AUC of 0.891. This panel represents an important step toward identifying DGF at an early stage so that more effective treatments can be developed to improve long-term graft outcomes.

Original languageEnglish (US)
Article number1600132
JournalProteomics - Clinical Applications
Volume11
Issue number7-8
DOIs
StatePublished - Jul 1 2017

Fingerprint

Delayed Graft Function
Transplants
Biomarkers
Proteome
Grafts
Assays
Urine
Kidney
Recovery
Proteins
Sensitivity and Specificity
Area Under Curve
Research Design
Design of experiments
Therapeutics
Research

Keywords

  • Disease biomarkers
  • Kidney transplant
  • Targeted proteomics
  • Urine

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Use of a Targeted Urine Proteome Assay (TUPA) to identify protein biomarkers of delayed recovery after kidney transplant. / Williams, Kenneth R.; Colangelo, Christopher M.; Hou, Lin; Chung, Lisa; Belcher, Justin M.; Abbott, Thomas; Hall, Isaac E.; Zhao, Hongyu; Cantley, Lloyd G.; Parikh, Chirag.

In: Proteomics - Clinical Applications, Vol. 11, No. 7-8, 1600132, 01.07.2017.

Research output: Contribution to journalArticle

Williams, KR, Colangelo, CM, Hou, L, Chung, L, Belcher, JM, Abbott, T, Hall, IE, Zhao, H, Cantley, LG & Parikh, C 2017, 'Use of a Targeted Urine Proteome Assay (TUPA) to identify protein biomarkers of delayed recovery after kidney transplant', Proteomics - Clinical Applications, vol. 11, no. 7-8, 1600132. https://doi.org/10.1002/prca.201600132
Williams, Kenneth R. ; Colangelo, Christopher M. ; Hou, Lin ; Chung, Lisa ; Belcher, Justin M. ; Abbott, Thomas ; Hall, Isaac E. ; Zhao, Hongyu ; Cantley, Lloyd G. ; Parikh, Chirag. / Use of a Targeted Urine Proteome Assay (TUPA) to identify protein biomarkers of delayed recovery after kidney transplant. In: Proteomics - Clinical Applications. 2017 ; Vol. 11, No. 7-8.
@article{8a09622eaa9a4fc3bfb695e955ecb0f1,
title = "Use of a Targeted Urine Proteome Assay (TUPA) to identify protein biomarkers of delayed recovery after kidney transplant",
abstract = "Purpose: Development of delayed graft function (DGF) following kidney transplant is associated with poor outcomes. An ability to rapidly identify patients with DGF versus those with immediate graft function (IGF) may facilitate the treatment of DGF and the research needed to improve prognosis. The purpose of this study was to use a Targeted Urine Proteome Assay to identify protein biomarkers of delayed recovery from kidney transplant. Experimental design: Potential biomarkers were identified using the Targeted Urine Proteome (MRM) Assay to interrogate the relative DGF/IGF levels of expression of 167 proteins in urine taken 12–18 h after kidney implantation from 21 DGF, 15 SGF (slow graft function), and 16 IGF patients. An iterative Random Forest analysis approach evaluated the relative importance of each biomarker, which was then used to identify an optimum biomarker panel that provided the maximum sensitivity and specificity with the least number of biomarkers. Conclusions and clinical relevance: Four proteins were identified that together distinguished DGF with a sensitivity of 77.4{\%}, specificity of 82.6{\%}, and AUC of 0.891. This panel represents an important step toward identifying DGF at an early stage so that more effective treatments can be developed to improve long-term graft outcomes.",
keywords = "Disease biomarkers, Kidney transplant, Targeted proteomics, Urine",
author = "Williams, {Kenneth R.} and Colangelo, {Christopher M.} and Lin Hou and Lisa Chung and Belcher, {Justin M.} and Thomas Abbott and Hall, {Isaac E.} and Hongyu Zhao and Cantley, {Lloyd G.} and Chirag Parikh",
year = "2017",
month = "7",
day = "1",
doi = "10.1002/prca.201600132",
language = "English (US)",
volume = "11",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "7-8",

}

TY - JOUR

T1 - Use of a Targeted Urine Proteome Assay (TUPA) to identify protein biomarkers of delayed recovery after kidney transplant

AU - Williams, Kenneth R.

AU - Colangelo, Christopher M.

AU - Hou, Lin

AU - Chung, Lisa

AU - Belcher, Justin M.

AU - Abbott, Thomas

AU - Hall, Isaac E.

AU - Zhao, Hongyu

AU - Cantley, Lloyd G.

AU - Parikh, Chirag

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Purpose: Development of delayed graft function (DGF) following kidney transplant is associated with poor outcomes. An ability to rapidly identify patients with DGF versus those with immediate graft function (IGF) may facilitate the treatment of DGF and the research needed to improve prognosis. The purpose of this study was to use a Targeted Urine Proteome Assay to identify protein biomarkers of delayed recovery from kidney transplant. Experimental design: Potential biomarkers were identified using the Targeted Urine Proteome (MRM) Assay to interrogate the relative DGF/IGF levels of expression of 167 proteins in urine taken 12–18 h after kidney implantation from 21 DGF, 15 SGF (slow graft function), and 16 IGF patients. An iterative Random Forest analysis approach evaluated the relative importance of each biomarker, which was then used to identify an optimum biomarker panel that provided the maximum sensitivity and specificity with the least number of biomarkers. Conclusions and clinical relevance: Four proteins were identified that together distinguished DGF with a sensitivity of 77.4%, specificity of 82.6%, and AUC of 0.891. This panel represents an important step toward identifying DGF at an early stage so that more effective treatments can be developed to improve long-term graft outcomes.

AB - Purpose: Development of delayed graft function (DGF) following kidney transplant is associated with poor outcomes. An ability to rapidly identify patients with DGF versus those with immediate graft function (IGF) may facilitate the treatment of DGF and the research needed to improve prognosis. The purpose of this study was to use a Targeted Urine Proteome Assay to identify protein biomarkers of delayed recovery from kidney transplant. Experimental design: Potential biomarkers were identified using the Targeted Urine Proteome (MRM) Assay to interrogate the relative DGF/IGF levels of expression of 167 proteins in urine taken 12–18 h after kidney implantation from 21 DGF, 15 SGF (slow graft function), and 16 IGF patients. An iterative Random Forest analysis approach evaluated the relative importance of each biomarker, which was then used to identify an optimum biomarker panel that provided the maximum sensitivity and specificity with the least number of biomarkers. Conclusions and clinical relevance: Four proteins were identified that together distinguished DGF with a sensitivity of 77.4%, specificity of 82.6%, and AUC of 0.891. This panel represents an important step toward identifying DGF at an early stage so that more effective treatments can be developed to improve long-term graft outcomes.

KW - Disease biomarkers

KW - Kidney transplant

KW - Targeted proteomics

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=85017367391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017367391&partnerID=8YFLogxK

U2 - 10.1002/prca.201600132

DO - 10.1002/prca.201600132

M3 - Article

C2 - 28261998

AN - SCOPUS:85017367391

VL - 11

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 7-8

M1 - 1600132

ER -